trending Market Intelligence /marketintelligence/en/news-insights/trending/GrOKFKtmNZ9RY17HXBLpZg2 content esgSubNav
In This List

Eli Lilly to collaborate with KeyBioscience for treating metabolic disorders

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Eli Lilly to collaborate with KeyBioscience for treating metabolic disorders

Eli Lilly & Co. entered an agreement with KeyBioscience AG to develop dual amylin calcitonin receptor agonists, or DACRAs — a potential new class of treatments for metabolic disorders such as type 2 diabetes.

The collaboration includes access to the DACRA platform with multiple molecules including KBP-042, KBP-089 and KBP-056.

KeyBioscience will receive $55 million in up-front payment as well as milestone-related payments and royalties on the future sales of successful candidates.

KeyBioscience has initiated phase 2 development with KBP-042. Other assets range from phase 1 to preclinical.

The transaction is subject to antitrust approval.